Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD | Zendy

Flory T. Muanda | Zendy; Matthew A. Weir | Zendy; Lavanya Bathini | Zendy; Kristin K. Clemens | Zendy; Vlado Perkovic | Zendy; Manish M. Sood | Zendy; Eric McArthur | Zendy; Jessica M. Sontrop | Zendy; Richard B. Kim | Zendy; Amit X. Garg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD

Author(s) -

Flory T. Muanda,

Matthew A. Weir,

Lavanya Bathini,

Kristin K. Clemens,

Vlado Perkovic,

Manish M. Sood,

Eric McArthur,

Jessica M. Sontrop,

Richard B. Kim,

Amit X. Garg

Publication year - 2020

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.08310520

Subject(s) - sitagliptin , medicine , heart failure , hazard ratio , confidence interval , proportional hazards model , cardiology , population , relative risk , diabetes mellitus , type 2 diabetes , endocrinology , environmental health

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a higher risk of congestive heart failure, particularly at higher doses. We compare the 1-year risk of death or hospitalization with congestive heart failure in patients with CKD newly prescribed sitagliptin at >50 versus ≤50 mg/d.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research